SCHEMBL4984893

SCHEMBL4984893

CCOC(=O)C1=C(N)CN(Cc2ccccc2)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.61
KMT2A Q03164 4/20 0.61
LMNA P02545 3/20 0.61
MAPT P10636 3/20 0.61
ADORA1 P30542 1/20 0.61
PRMT1 Q99873 1/20 0.52
CHRM2 P08172 2/20 0.51
CHRM4 P08173 2/20 0.51
CHRM5 P08912 2/20 0.51
CHRM1 P11229 2/20 0.51
CHRM3 P20309 2/20 0.51
CASP3 P42574 2/20 0.49
GAA P10253 2/20 0.48
NPC1 O15118 1/20 0.48
TNF P01375 1/20 0.48
RAB9A P51151 1/20 0.48
NOD2 Q9HC29 1/20 0.48
NOD1 Q9Y239 1/20 0.48
POLB P06746 1/20 0.48
MAPK1 P28482 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15420762 0.90 MEN1 (0.61) MEN1KMT2ALMNAMAPTADORA1
SCHEMBL7917885 0.88 LMNA (0.53) MEN1KMT2ALMNAMAPTADORA1
SCHEMBL4350099 0.87 CHRM2 (0.50) MEN1KMT2ALMNAMAPTADORA1
SCHEMBL20300563 0.87 MEN1 (0.57) MEN1KMT2ALMNAMAPTADORA1
SCHEMBL12617960 0.87 MEN1 (0.57) MEN1KMT2ALMNAMAPTADORA1
SCHEMBL20300559 0.85 MEN1 (0.55) MEN1KMT2ALMNAMAPTADORA1
SCHEMBL28027523 0.85 MEN1 (0.55) MEN1KMT2ALMNAMAPTADORA1
SCHEMBL1097364 0.84 CHRM5 (0.62) MEN1KMT2ALMNAMAPTADORA1
SCHEMBL30932871 0.82 MEN1 (0.56) MEN1KMT2ALMNAMAPTADORA1
SCHEMBL17474536 0.81 CHRM5 (0.76) CHRM2CHRM4CHRM5CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025094035-A1 TOLL-LIKE RECEPTOR AGONISTS AND CONJUGATES THEREOF PFIZER INC. (US) 2025-05-08 WO disclosed
CN-113061132-B Condensed ring lactam compound, preparation method and application 上海凌达生物医药有限公司 2023-11-14 CN disclosed
CN-116143806-A Nitrogen-containing heterocyclic compound, preparation method and application 上海凌达生物医药有限公司 2023-05-23 CN disclosed
WO-2022087375-A1 NOVEL HETEROCYCLIC COMPOUNDS SPECTRUM PHARMACEUTICALS, INC. (US) 2022-04-28 WO disclosed
WO-2022087375-A1 NOVEL HETEROCYCLIC COMPOUNDS SPECTRUM PHARMACEUTICALS, INC. (US) 2022-04-28 WO disclosed
CN-112094269-B Saturated six-membered ring heterocyclic compound, preparation method and application 上海凌达生物医药有限公司 2021-12-07 CN disclosed
CN-112142735-B Condensed cyanopyridine compound, preparation method and application 上海凌达生物医药有限公司 2021-09-17 CN disclosed
CN-113061132-A Condensed ring lactam compound, preparation method and application 上海凌达生物医药有限公司 2021-07-02 CN disclosed
US-20210094919-A1 KRAS MUTANT PROTEIN INHIBITORS JACOBIO PHARMACEUTICALS CO., LTD. 2021-04-01 US disclosed
CN-112552295-A KRAS mutein inhibitors 北京加科思新药研发有限公司 2021-03-26 CN disclosed
WO-2015148344-A2 TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF MERCK SHARP & DOHME CORP. (US) 2015-10-01 WO disclosed
US-20080039478-A1 Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof RENOVIS, INC. 2008-02-14 US disclosed
US-20080039478-A1 Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof RENOVIS, INC. 2008-02-14 US disclosed
US-20080039478-A1 Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof RENOVIS, INC. 2008-02-14 US disclosed
EP-1860942-A2 BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF Renovis, Inc. (US) 2007-12-05 EP disclosed
US-7297700-B2 Bicycloheteroaryl compounds as P2X7 modulators and uses thereof RENOVIS, INC. (US) 2007-11-20 US disclosed
US-7297700-B2 Bicycloheteroaryl compounds as P2X7 modulators and uses thereof RENOVIS, INC. (US) 2007-11-20 US disclosed
US-7297700-B2 Bicycloheteroaryl compounds as P2X7 modulators and uses thereof RENOVIS, INC. (US) 2007-11-20 US disclosed
WO-2006102610-A2 BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF RENOVIS, INC. (US) 2006-09-28 WO disclosed
US-20060217448-A1 e.g. 4-benzyl-N-[2-(2-chlorophenyl)ethyl]-4,7,9-triazabicyclo[4.4.0]deca-7,9,11-triene-10-carboxamide; antiinflammatory and analgesic agent; rheumatoid arthritis, osteoarthritis, Parkinson's disease, uveitis, asthma, cardiovascular conditions, myocardial infarction RENOVIS, INC. 2006-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217448-A1 e.g. 4-benzyl-N-[2-(2-chlorophenyl)ethyl]-4,7,9-triazabicyclo[4.4.0]deca-7,9,11-triene-10-carboxamide; antiinflammatory and analgesic agent; rheumatoid arthritis, osteoarthritis, Parkinson's disease, uveitis, asthma, cardiovascular conditions, myocardial infarction PARK7, UACA, PTGER4 MEN1 4084/4885KMT2A 3134/4885LMNA 1935/4885
US-20080039478-A1 Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof P2RX7, P2RX3, P2RX2 MEN1 4853/4885KMT2A 4614/4885LMNA 1911/4885
US-20210094919-A1 KRAS MUTANT PROTEIN INHIBITORS KRAS, NRAS, APC MEN1 1398/4885KMT2A 2569/4885LMNA 3837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.